Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: Application to dynamic contrast-enhanced MRI biomarkers

Magnetic Resonance in Medicine

Volumn 71, Issue 3, 2014, Pages 1299-1311

  Rose, Chris J ^a   O'Connor, James P B ^a,b   Cootes, Tim F ^a   Taylor, Chris J ^a   Jayson, Gordon C ^a   Parker, Geoff J M ^a   Waterton, John C ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

dynamic contrast enhanced magnetic resonance imaging; heterogeneity; image analysis; imaging based trials

Indexed keywords

GRAPHIC METHODS; IMAGE ANALYSIS; MAGNETIC RESONANCE IMAGING;

CONFIDENCE INTERVAL; DISTRIBUTION ANALYSIS; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; DYNAMIC CONTRAST ENHANCED MRI; HETEROGENEITY; HISTOGRAM ANALYSIS; PHYSIOLOGICAL MEASUREMENT; SIGNIFICANCE TESTING;

IMAGE ENHANCEMENT;

BEVACIZUMAB; BIOLOGICAL MARKER; CONTRAST MEDIUM; MONOCLONAL ANTIBODY;

ARTICLE; BRAIN MAPPING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; HISTOGRAM; HUMAN; IMAGE ANALYSIS; INDEXED DISTRIBUTION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SIMULATION; STATISTICAL SIGNIFICANCE; COLORECTAL NEOPLASMS; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC USE; IMAGE ENHANCEMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SPATIOTEMPORAL ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DATA INTERPRETATION, STATISTICAL; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SPATIO-TEMPORAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894503784     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.24755     Document Type: Article

References (33)

1. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Tofts PS,. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imag 1997; 7: 91-101.
3. Miles KA,. Functional computed tomography in oncology. Eur J Cancer 2002; 38: 2079-2084.
4. Astrakas L, Argyropoulou M,. Shifting from region of interest (ROI) to voxel-based analysis in human brain mapping. Pediatr Radiol 2010; 40: 1857-1867.
5. Williams TG, Holmes AP, Waterton JC, Maciewicz RA, Hutchinson CE, Moots RJ, Nash AFP, Taylor CJ,. Anatomically corresponded regional analysis of cartilage in asymptomatic and osteoarthritic knees by statistical shape modelling of the bone. IEEE Trans Med Imag 2010; 29: 1541-1559.
6. Tofts PS, Benton CE, Weil RS, Tozer DJ, Altmann DR, Jäger HR, Waldman AD, Rees JH,. Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Reson Imag 2007; 25: 208-214.
7. Li KL, Wilmes LJ, Henry RG, et al. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imag 2005; 22: 511-519.
8. Jackson A, O'Connor JPB, Parker GJM, Jayson GC,. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13: 3449-3459.
9. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC,. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88: 1592-1597.
10. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR,. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Brit J Cancer 2003; 89: 1889-1895.
11. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG,. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1309-1315.
12. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K,. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imag 2007; 25: 1-13.
13. O'Connor E, Fieller N, Holmes A, Waterton JC, Ainscow E,. Functional principal component analyses of biomedical images as outcome measures. J Roy Stat Soc C-App 2010; 59: 57-76.
14. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imag 2003; 18: 467-477.
15. Berry LR, Barck KH, Go MA, et al. Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn Reson Med 2008; 60: 64-72.
16. Galbán CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009; 15: 572-576.
17. Schmid VJ, Whitcher B, Padhani AR, Taylor NJ, Yang GZ,. A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. Magn Reson Med 2009; 61: 163-174.
18. Alic L, van Vliet M, van Dijke CF, Eggermont AM, Veenland JF, Niessen WJ,. Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? Phys Med Biol 2011; 56: 1601-1616.
19. Canuto HC, McLachlan C, Kettunen MI, Velic M, Krishnan AS, Neves AA, deBacker M, Hu DE, Hobson MP, Brindle KM,. Characterization of image heterogeneity using 2D Minkowski functionals increases the sensitivity of detection of a targeted MRI contrast agent. Magn Reson Med 2009; 61: 1218-1224.
20. Rose CJ, Mills SJ, O'Connor JP, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009; 62: 488-499.
21. O'Connor JP, Carano RA, Clamp AR, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009; 15: 6674-6682.
22. Rose CJ, Hubbard PL, Cootes TF, Taylor CJ, Naish JH, Parker GJ, Young SS, Waterton JC,. Are two samples of parametric images statistically different? Novel significane tests on samples of density estimates, with application to ventilation-to-perfusion mapping of the lung in COPD using oxygen-enhanced MRI. In Proceedings of the 20th Annual Meeting of ISMRM, Melbourne, Australia, 2012. p. 755.
23. Buonaccorsi GA, Roberts C, Cheung S, Watson Y, Davies K, Jackson A, Jayson GC, Parker GJM,. Tracer kinetic model-driven registration for dynamic contrast enhanced mri time series. In:, Hutchison D, Kanade T, Kittler J, et al. editors, Medical image computing and computer-assisted intervention-MICCAI 2010, Vol. 3749 of Lecture Notes in Computer Science. Springer Berlin Heidelberg; 2005. pp. 91-98.
24. Benjamini Y, Yekutieli D,. The control of the false discovery rate in multiple testing under dependency. Ann Statist 2001; 29: 1165-1188.
25. Tufte ER,. The visual display of quantitative information. Cheshire, CT: Graphics Pr; 2001.
26. Guideline for Good Clinical Practice E6(R1). International Conference on Harmonisation (ICH) Topic E 6 (R1) Guideline for Good Clinical Practice; 1996.
27. Machin D, Campbell MJ, Tan SB, Tan SH,. Sample size tables for clinical studies, 3rd ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2008.
28. O'Connor JPB, Jackson A, Parker GJM, Jayson GC,. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195.
29. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC,. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012; 9: 167-177.
30. Fram EK, Herfkens RJ, Johnson GA, Glover GH, Karis JP, Shimakawa A, Perkins TG, Pelc NJ,. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imag 1987; 5: 201-208.
31. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM,. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer 1987; 59: 1547-1553.
32. Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, Jackson A, Watson Y, Davies K, Jayson GC,. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced mri. Magn Reson Med 2006; 56: 993-1000.
33. O'Connor JP, Rose CJ, Jackson A, et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 2011; 105: 139-145